Selected article for: "clinical observation and study clinical observation"
Author: Landi, Lorenza; Ravaglia, Claudia; Russo, Emanuele; Cataleta, Pierluigi; Fusari, Maurizio; Boschi, Andrea; Giannarelli, Diana; Facondini, Francesca; Valentini, Ilaria; Panzini, Ilaria; Lazzari-Agli, Luigi; Bassi, Paolo; Marchionni, Elisa; Romagnoli, Rossella; De Giovanni, Raffaella; Assirelli, Marina; Baldazzi, Federica; Pieraccini, Fabio; Rametta, Giovanna; Rossi, Lucia; Santini, Luca; Valenti, Ivana; Cappuzzo, Federico
Title: Blockage of interleukin-1β with canakinumab in patients with Covid-19
  • Cord-id: l2ndw1z0
  • Document date: 2020_12_11
    • ID: l2ndw1z0
    Snippet: There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO(2)/FiO(2) increased from 160 (range 53–409, IQR 122â€
    Document: There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO(2)/FiO(2) increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 10(9)/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • absolute lymphocyte count and administration hospitalization: 1
    • absolute lymphocyte count and admission death: 1, 2
    • absolute lymphocyte count and long follow: 1
    • activity block and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory distress syndrome and additional information: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and additional study: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress syndrome and admission death: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory distress syndrome and low flow oxygen: 1, 2, 3
    • acute respiratory distress syndrome patient and low flow oxygen: 1
    • acute respiratory syndrome and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional weight: 1
    • acute respiratory syndrome and administration hospitalization: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and admission death: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir control trial: 1
    • acute respiratory syndrome and low flow oxygen: 1, 2, 3, 4, 5, 6